These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19359152)

  • 1. Prominent role of low HDL-cholesterol in explaining the high prevalence of the metabolic syndrome in polycystic ovary syndrome.
    Gambineri A; Repaci A; Patton L; Grassi I; Pocognoli P; Cognigni GE; Pasqui F; Pagotto U; Pasquali R
    Nutr Metab Cardiovasc Dis; 2009 Dec; 19(11):797-804. PubMed ID: 19359152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher high-density lipoprotein cholesterol in African-American women with polycystic ovary syndrome compared with Caucasian counterparts.
    Koval KW; Setji TL; Reyes E; Brown AJ
    J Clin Endocrinol Metab; 2010 Sep; 95(9):E49-53. PubMed ID: 20534766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.
    Yildiz BO; Yarali H; Oguz H; Bayraktar M
    J Clin Endocrinol Metab; 2003 May; 88(5):2031-6. PubMed ID: 12727950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome.
    Lerchbaum E; Schwetz V; Giuliani A; Pieber TR; Obermayer-Pietsch B
    Fertil Steril; 2012 Nov; 98(5):1318-25.e1. PubMed ID: 22835450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance.
    Coviello AD; Legro RS; Dunaif A
    J Clin Endocrinol Metab; 2006 Feb; 91(2):492-7. PubMed ID: 16249280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS).
    Kumar A; Woods KS; Bartolucci AA; Azziz R
    Clin Endocrinol (Oxf); 2005 Jun; 62(6):644-9. PubMed ID: 15943823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimüllerian hormone levels and cardiometabolic risk in young women with polycystic ovary syndrome.
    Feldman RA; O'Neill K; Butts SF; Dokras A
    Fertil Steril; 2017 Jan; 107(1):276-281. PubMed ID: 27842995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome.
    Rizzo M; Longo RA; Guastella E; Rini GB; Carmina E
    J Endocrinol Invest; 2011 Jun; 34(6):422-6. PubMed ID: 20959718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are progranulin levels associated with polycystic ovary syndrome and its possible metabolic effects in adolescents and young women?
    Ersoy AO; Tokmak A; Ozler S; Oztas E; Ersoy E; Celik HT; Erdamar H; Yilmaz N
    Arch Gynecol Obstet; 2016 Aug; 294(2):403-9. PubMed ID: 27071619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperandrogenemia in polycystic ovary syndrome: exploration of the role of free testosterone and androstenedione in metabolic phenotype.
    Lerchbaum E; Schwetz V; Rabe T; Giuliani A; Obermayer-Pietsch B
    PLoS One; 2014; 9(10):e108263. PubMed ID: 25310562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between female sexual function and metabolic features of the polycystic ovary syndrome in Turkish women of reproductive age.
    Cevik Dogan M; Yoldemir T
    Gynecol Endocrinol; 2024 Dec; 40(1):2362249. PubMed ID: 38913084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total testosterone to dihydrotestosterone ratio assessed by LC-MS/MS predicts a worse metabolic profile not only in PCOS patients.
    Ambroziak U; Kuryłowicz A; Kępczyńska-Nyk A; Bartoszewicz Z; Kondracka A; Jaźwiec R; Samborowska E; Dadlez M; Wysłouch-Cieszyńska A; Bednarczuk T
    Ginekol Pol; 2017; 88(1):5-8. PubMed ID: 28157253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACC/AHA 2017 definition of high blood pressure: implications for women with polycystic ovary syndrome.
    Marchesan LB; Spritzer PM
    Fertil Steril; 2019 Mar; 111(3):579-587.e1. PubMed ID: 30827526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacy of different androgens measured by LC-MS/MS in representing hyperandrogenemia and an evaluation of adrenal-origin androgens with a dexamethasone suppression test in patients with PCOS.
    Chen F; Chen M; Zhang W; Yin H; Chen G; Huang Q; Yang X; Chen L; Lin C; Yin G
    J Ovarian Res; 2021 Feb; 14(1):32. PubMed ID: 33583431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome.
    Faloia E; Canibus P; Gatti C; Frezza F; Santangelo M; Garrapa GG; Boscaro M
    J Endocrinol Invest; 2004 May; 27(5):424-9. PubMed ID: 15279073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased chemerin serum levels in hyperandrogenic and normoandrogenic women from Argentina with polycystic ovary syndrome.
    Abruzzese GA; Gamez J; Belli SH; Levalle OA; Mormandi E; Otero P; Graffigna MN; Cerrone GE; Motta AB
    Gynecol Endocrinol; 2020 Dec; 36(12):1057-1061. PubMed ID: 32496833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dehydroepiandrosterone sulfate/free androgen index ratio predicts a favorable metabolic profile in patients with polycystic ovary syndrome.
    Nadir A; Temizkan S; Ozderya A; Temizkan O; Orbay E; Aydin K
    Gynecol Endocrinol; 2019 Feb; 35(2):128-132. PubMed ID: 30324855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alanine Aminotransferase Is a Marker of Lipotoxicity Consequences and Hyperandrogenemia in Women with Polycystic Ovary Syndrome.
    Belan M; Pelletier C; Baillargeon JP
    Metab Syndr Relat Disord; 2017 Apr; 15(3):145-152. PubMed ID: 28339345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic comparison of polycystic ovarian syndrome and control women in Middle Eastern and UK Caucasian populations.
    Butler AE; Abouseif A; Dargham SR; Sathyapalan T; Atkin SL
    Sci Rep; 2020 Nov; 10(1):18895. PubMed ID: 33144665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of a new anthropometric indicator - VAI (Visceral Adiposity Index) in the evaluation of metabolic and hormonal disorders in women with polycystic ovary syndrome.
    Brończyk-Puzoń A; Jagielski P; Kulik-Kupka K; Koszowska A; Nowak J; Zubelewicz-Szkodzińska B
    Adv Clin Exp Med; 2017 Aug; 26(5):825-828. PubMed ID: 29068579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.